Advanced glycation end products (AGEs) are chemical compounds that are formed in nonenzymatic reactions between reducing sugars or carbohydrates and proteins, lipids or nucleic acids. AGEs accumulation in tissues and blood serum has been implicated in diabetes and aging-related pathologies. Nanoemulsions have emerged as promising delivery systems for proteins, peptides, nucleic acids and small molecule drugs. Nanoemulsions are dispersed systems containing droplets of oil and water stabilized by an interfacial film of surfactants, with average droplet sizes usually ranging between 20-500 nanometers. They can enhance solubility and bioavailability of hydrophobic drugs and protect vulnerable compounds such as proteins, peptides and nucleic acids.

The global Advanced Glycation End Products Market is estimated to be valued at US$ 3,469.95 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/advanced-glycation-end-products-market-4350

Market key trends:

Continuous research and development activities are expected to generate demand for nanoemulsions in the pharmaceutical industry. Researchers are developing novel nanoemulsion-based drug delivery systems using advanced nanotechnologies to improve bioavailability and therapeutic efficacy of various drugs. For instance, in June 2019, a team of engineers from the MIT announced that they are developing a method of converting liquid nanoemulsions into solid gels. This novel approach could allow for sustained drug release from gels over periods ranging from days to months. Such innovations are expected to boost demand for advanced nanoemulsion delivery technologies in the global advanced glycation end products market during the forecast period.

Porter’s Analysis

Threat of new entrants: The advanced glycation end products market requires high RD investments and regulatory approvals, limiting threat of new entrants.
Bargaining power of buyers: Individual consumers have low bargaining power due to availability of limited product options. However, large pharmaceutical companies enjoy high bargaining power.
Bargaining power of suppliers: Key raw material suppliers enjoy bargaining power due to specialized requirements. However, the presence of substitutes keeps their power in check.
Threat of new substitutes: Ongoing research on developing new drug delivery technologies poses threat of substitutes.
Competitive rivalry: The market is moderately competitive with major players differentiating through continuous innovations.

Key Takeaways

The global advanced glycation end products market is expected to witness high growth. The North American region currently dominates the market due to high research activities and increasing burden of chronic diseases.

Regional analysis: North America is the leading region due to growing diabetes population and supportive government initiatives for research. However, Asia Pacific is likely to emerge as the fastest growing market over the forecast period owing to rising healthcare expenditure, healthcare reforms, and increasing focus of major players.

Key players: Continuous research and development activities are expected to generate demand for nanoemulsions in the pharmaceutical industry. In June 2019, a team of engineers from the MIT announced that they are developing a method of converting liquid nanoemulsions into solid gels. Key players operating in the advanced glycation end products market are Lonza Group Ltd., Thermo Fisher Scientific, Abcam PLC, Merck KgaA, and Cayman Chemical Company